Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Merck & Co., Inc. — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.04 (market cap $12.87B), while Merck & Co., Inc. trades at $144.93 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 27.3× iShares JPMorgan USD Emerging Markets Bond ETF's market cap, and Merck & Co., Inc. pays a 2.39% dividend while iShares JPMorgan USD Emerging Markets Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and Merck & Co., Inc. for 98 Days on average.
| EMB | MRK | |
|---|---|---|
Market Cap | $12.87B | $351.28B |
Volume | 14,946,002 | 7,969,665 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $156.43 |
52-Week Low | $90.14 | $82.49 |
Typical Hold Time | 50 Days | 98 Days |
Enterprise Value | — | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.96 with minimal daily movement (+0.2%), showing technical bearish signals from moving averages while oscillators remain neutral. The stock faces resistance at $91-92 with support at $90. Recent dividend declarations of $0.41-0.44 per share provide income appeal, though key financial ratios remain undisclosed in current data.
The outlook appears cautious with technical indicators signaling bearish momentum. Income-focused investors may find value in the dividend yield, but limited fundamental data availability and bearish technical signals suggest careful evaluation is warranted. Market risks include broader economic pressures affecting bond yields and emerging market exposure.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
